…
StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, metabolic syndrome, neuropathy, and kidney functions in the United States. It develops and manufactures the eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and the eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of the shoulder, waist, back, neck, upper and lower extremities (arms and legs). The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
STME (STME.US) is a Pink Sheets–listed company with limited publicly available disclosures, and its core business is not clearly documented in accessible filings. Major long-term growth drivers cannot be identified from public sources, so the equity may appeal primarily to investors seeking speculative exposure to any future operational or disclosure developments.
Primary investment risks include low trading liquidity, thin analyst coverage, potential reporting and governance deficiencies common to Pink Sheets issuers, and execution or financing uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-05-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-05-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
| Income before tax | -0.90M | -0.57M | -0.14M | -0.50M | -0.70M |
| Net income | -0.90M | -0.57M | -0.14M | -0.50M | -0.70M |
| Selling general administrative | 0.38M | 0.21M | 0.29M | 0.36M | 0.52M |
| Gross profit | - | - | 0.00M | 0.00M | 0.00M |
| Reconciled depreciation | - | - | - | 0.00M | 0.00M |
| Ebit | - | - | -0.35M | -0.45M | - |
| Ebitda | -0.82M | -0.53M | -0.08M | -0.45M | - |
| Depreciation and amortization | - | - | 0.27M | 0.00M | - |
| Operating income | -0.82M | -0.50M | -0.31M | -0.45M | -0.67M |
| Other operating expenses | 0.82M | 0.50M | 0.31M | 0.45M | - |
| Interest expense | 0.07M | 0.04M | 0.06M | 0.05M | - |
| Net interest income | -0.07M | -0.04M | -0.06M | -0.05M | -0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Total operating expenses | 0.82M | 0.52M | 0.31M | 0.45M | 0.68M |
| Cost of revenue | - | - | 0.00M | 0.00M | 0.00M |
| Total other income expense net | -0.07M | -0.06M | 0.12M | -0.05M | - |
| Net income from continuing ops | -0.90M | -0.57M | -0.14M | -0.50M | -0.70M |
| Breakdown | 2026-05-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-05-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
| Total assets | 0.08M | 0.02M | 0.05M | 0.10M | 0.04M |
| Other current assets | -0.00M | 0.01M | 0.00M | 0.00M | - |
| Total liab | 1.89M | 1.27M | 0.87M | 2.49M | 2.05M |
| Total stockholder equity | -1.81M | -1.25M | -0.83M | -2.39M | -2.01M |
| Other current liab | -0.69M | 0.03M | 0.27M | 1.08M | - |
| Common stock | 0.02M | 0.02M | 0.30M | 0.06M | - |
| Capital stock | 0.02M | 0.02M | 0.02M | 0.06M | 0.06M |
| Retained earnings | -11.76M | -10.86M | -10.30M | -10.15M | -9.66M |
| Other assets | 0.08M | 0.01M | -0.00M | -0.00M | - |
| Cash | 0.00M | 0.01M | 0.04M | 0.10M | 0.02M |
| Total current liabilities | 0.36M | 0.32M | 0.87M | 2.49M | 2.05M |
| Net debt | 0.69M | -0.01M | 0.27M | 0.90M | 0.59M |
| Short term debt | 0.69M | 0.46M | 0.31M | 1.00M | - |
| Short long term debt | 0.82M | 0.46M | 0.31M | 1.00M | 0.62M |
| Short long term debt total | 0.69M | 0.46M | 0.31M | 1.00M | - |
| Other stockholder equity | 9.47M | 18.66M | 8.74M | 7.27M | - |
| Total current assets | 0.00M | 0.01M | 0.05M | 0.10M | 0.04M |
| Net receivables | 0.00M | - | 0.00M | 0.00M | - |
| Inventory | - | - | - | -0.01M | - |
| Accounts payable | 0.36M | 0.32M | 0.29M | 0.41M | 0.44M |
| Accumulated other comprehensive income | 0.45M | 0.08M | 0.44M | 0.43M | - |
| Non currrent assets other | 0.08M | - | 0.00M | 0.00M | - |
| Non current assets total | 0.08M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2026-05-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-05-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
| Investments | - | - | - | - | 0.00M |
| Net borrowings | 0.30M | 0.11M | 0.02M | 0.35M | 0.29M |
| Total cash from financing activities | 0.30M | 0.11M | 0.09M | 0.35M | 0.45M |
| Net income | -0.90M | -0.57M | -0.14M | -0.50M | -0.70M |
| Change in cash | -0.01M | -0.03M | -0.05M | 0.07M | 0.00M |
| Begin period cash flow | 0.01M | 0.04M | 0.10M | 0.02M | 0.02M |
| End period cash flow | 0.00M | 0.01M | 0.04M | 0.10M | 0.02M |
| Total cash from operating activities | -0.31M | -0.14M | -0.15M | -0.27M | -0.45M |
| Depreciation | - | - | - | 0.00M | 0.00M |
| Change to inventory | - | - | - | - | 0.00M |
| Other cashflows from financing activities | 0.30M | 0.11M | - | 0.16M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.24M | 0.26M | 0.12M | 0.10M | 0.14M |
| Other non cash items | 0.34M | 0.42M | -0.12M | 0.12M | 0.06M |
| Free cash flow | -0.31M | -0.14M | -0.15M | -0.27M | -0.45M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| STME STME |
- -% |
0.24 | - | - | 34548.53 | - | 103692.30 | -31.71 |
| ABT Abbott Laboratories |
-0.10 0.10% |
103.87 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
- -% |
100.61 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-0.13 0.04% |
313.08 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
0.64 1.35% |
48.14 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, metabolic syndrome, neuropathy, and kidney functions in the United States. It develops and manufactures the eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and the eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of the shoulder, waist, back, neck, upper and lower extremities (arms and legs). The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. David M. Jeffs | President, CEO & Director | 1970 |
| Ms. Yanika Silina C.M.A., C.P.A. | CFO, Treasurer & Corporate Secretary | 1978 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.